Chapter 755: The Greedy Hunter

That night, Xia Yu gathered all the members of the acquisition team to summarize the results of the day and agree on tomorrow's plan based on the situation.

First, they reported on the current situation of each team.

Xia Yu's team need not be mentioned, as they had taken it all that day.

Peter Lynch's second team was responsible for York Capital.

He reported to Xia Yu, 'Chairman, today we negotiated with the CEO of York Capital all day, and they have agreed to sell their shares. The difficulty now is that we can't agree on a price.'

'York Capital is asking for 55 million US dollars, and due to time constraints, the negotiations have ended.'

Xia Yu nodded slightly and looked at the leader of the third team, Brandon Garth, who immediately said, 'Chairman, Conston Capital is very confident in Genentech and has always refused to sell its stake. It wasn't until the afternoon that we persuaded them to agree to sell their stake, but they asked for a very high price, 21.5 million US dollars for 8.6% of the stake!'

At this price, it can be seen that they value Genentech at 250 million US dollars, which is 50 million US dollars higher than the valuation of Coller Perkins!

But Xia Yu also expressed his understanding, because at the beginning, he had predicted that Constant Capital would be the most negative about selling their shares.

After all, they joined in the third round of financing, after defeating a large number of competitors, so they were destined to have the most confidence in Genentech.

And since they were the latest to enter, it meant that their appetite would be the greatest. They also had the financial strength to take on this risk and the strength to wait for Genentech to go public.

Unlike Coller Perkins, which had weak capital and had never seen the big time, Xia Yu's higher offer made them surrender obediently.

After motioning for Brandon Garth to sit down, Xia Yu said with a smile, 'Actually, the situation is not bad. Although we didn't succeed that day, both of your teams successfully convinced them to sell their shares, the only difference being the price.'

'York Capital's valuation of Genentech is 220 million US dollars, while Conston Capital's valuation is 250 million US dollars. The valuation of Coller Perkins, which I was responsible for closing, is only 200 million US dollars. There is indeed a big difference here.'

'But never mind, Conston Capital has the lowest stake, so even if the valuation is higher, it's only an extra $10 million or so. Agree to it!'

'You can tell them the price of Coller Perkins today to put pressure on them!'

'I have one request: tomorrow, the acquisition must be completed. This is the company's first move, and I don't want any surprises! I hope you can do well!'

Everyone's hearts sank, and they all promised in unison.

They then continued to discuss detailed strategies for the takeover, striving to get York Capital and Conston Capital to follow the lead of Polaris Capital the next day!

Early the next morning, Peter Lynch and Brandon Gus set off again.

Xia Yu, on the other hand, led his subordinates to Genentech.

He hadn't forgotten that Professor Herb Boyle wanted to meet with him.

Moreover, the shares in Professor Herb Boyle's hands were also something he coveted.

Xia Yu waited in the reception room for less than five minutes before he saw an elderly man in his fifties wearing glasses walk in.

Xia Yu recognised him immediately from the photo: this was Professor Herb Boyer.

He immediately stood up and said with a slight air of respect, 'Hello, Professor Herb Boyer, I am the chairman of Polaris Capital. My name is Xia Yu, you can call me Xia.'

Professor Herb Boyer was not overbearing. He smiled, shook Xia Yu's hand, and awkwardly called Xia Yu's name, saying, 'Hello, Mr. Xia! Please sit!'

'Thank you, please sit down too!'

After taking their seats, Professor Herb Boyer asked bluntly, 'Mr. Xia, yesterday Robert Swanson already told me that the company's shares had been sold to you, and you also agreed to my terms. Now that we are face to face, I want to know what your purpose is in acquiring Genentech and what your attitude is?'

As expected of someone in scientific research, his words are straightforward, but this personality is just right, not so full of tricks, as long as you hit the right spot, you will actually get along very well.

Xia Yu smiled and said, 'Professor Herb Boyer, the reason we acquired Genentech is because we have great expectations for you. We believe that your research can benefit the world, so we are willing to help you promote your research results to the world and incidentally receive some remuneration in the process.'

Xia Yu's words were very artful. Even Professor Herb Boyer, who didn't like people to flatter him, couldn't help but raise the corners of his mouth and soften his expression a little. He felt much closer to Xia Yu.

Professor Herb Boyer forced a smile and said, 'Mr. Xia, if that's really your attitude, then I welcome you!'

Xia Yu immediately nodded, saying the obvious: 'Of course, we will fully support your research.'

'By the way, Professor Herb Boyer, we have high hopes for you, so in addition to acquiring the equity of Coller Perkins, we are also acquiring the equity of York Capital and Conston Capital.'

With just a few words, Xia Yu already knew the nature of Professor Herb Boyer, so in order to avoid misunderstandings, he made things clear.

Professor Herb Boyer really didn't know this news. He frowned, stared at Xia Yu, and said bluntly, 'If you acquire the equity of these two companies, the listing process of Genentech will be terminated, but my research and the production of patents require a large amount of capital!'

Xia Yu looked him in the eye and immediately said, 'This is not a problem, Professor Herb Boyer. No matter how much capital you need, we, Polaris Capital, can inject it! As long as you need it!'

After saying this, Xia Yu, in order to dispel Professor Herb Boyer's doubts, also diverted his thoughts, saying, 'Professor Herb Boyer, in fact, you should know that there are both advantages and disadvantages to going public. If Genentech encounters difficulties in the future, the stock market will exert tremendous pressure on you, your plans will be subject to stricter scrutiny, and the media will keep shining their lights on you, making it impossible for you to conduct research in peace!'

Xia Yu's words make a lot of sense. Professor Herb Boyer has also looked into the advantages and disadvantages of the stock market in his spare time, and naturally is aware of past cases.

'As far as I know, Genentech went public because the next phase of research and expansion requires a large sum of money, which we can afford now. I hope you can avoid being disturbed by the noisy outside world, and we will do our best to create a better research environment for you.'

Professor Herb Boyer was able to win the Nobel Prize, so naturally he is a person who is fascinated by experiments. If it were not for the fact that the funds required for the next expansion were too large, the three venture capital firms might not have been able to afford it, and he would not have been encouraged to agree to the company's application for listing.

Now that only two of his research results have come out, and both are still under review, they have not yet been put into production, and the risk still exists.

Since Xia Yu's Polaris Capital is willing to take over and continue, he also hopes to continue his research in peace.

As for the dilution of his equity after the injection of capital by Polaris Capital, he doesn't care. He is not keen on money. He has even had the idea of setting up a research fund with his assets after his death to support the research of newcomers in the field of DNA.

There is a large element of chance and luck in his success, but Lady Luck doesn't smile on everyone all the time. He therefore hopes that newcomers will not also struggle to seek the truth due to the difficult research conditions.

'Mr Xia, welcome to the team!'

Professor Herb Boyle said with a smile.

'Professor Herb Boyle, thank you, I believe we will get along very well in the future!' Xia Yu smiled and shook his hand again.

Professor Herb Boyle nodded with a smile, 'I hope so!'

'Now the company's funds are running low, after you have completed the acquisition, I hope you can inject funds as soon as possible!'

'No problem, if the acquisition can be completed today, then we can inject funds at any time, everything is based on your wishes!'

...

Xia Yu had a very pleasant chat with Professor Herb Boyle, but the latter was preoccupied with his own experiment. After resolving his doubts, he proposed to take his leave and hurried back to the laboratory.

That afternoon, the acquisitions of both groups were completed.

Peter Lynch cited the case of Coller Perkins, and York Capital's psychological defenses collapsed at once. In the end, they transferred 25% of the equity they held at a price of 51 million US dollars.

Brandon Garth, on the other hand, also used every means at his disposal to reduce the valuation of Genentech to 220 million US dollars.

Therefore, the 8.6% stake held by Conston Capital was sold for 189.2 million US dollars.

At this point, Polaris Capital had spent a total of 119.92 million US dollars to acquire a 58.6% stake and become the largest shareholder of Genentech.

Xia Yu was very satisfied with this price.

He knew that the capital market was crazy about Genentech, and that according to historical trends, the stock price would rise from 35 US dollars to a high of 88 US dollars on the day of Genentech's IPO.

Even if the closing price was lower, it would still exceed 70 US dollars, and the market value would directly reach 300 million US dollars. Now, by cutting in half a year early, the valuation of Genentech had been kept under 200 million US dollars, which was a good deal.

Of course, if you also consider the future market value of Genentech, which could reach 100 billion US dollars, then it was even more worthwhile!

After completing the acquisition, Xia Yu immediately approached Professor Herb Boyer to discuss the capital injection.

In order to make a good impression, Xia Yu was not too demanding and valued Genentech at 210 million US dollars.

And in order to take over as much equity as possible, Xia Yu, from the perspective of Professor Herb Boyer, constantly encouraged him to make big leaps forward, purchase newer and better laboratory equipment, build a top-notch laboratory, and directly construct a large-scale factory.

In short, spend as much as you can, just to take advantage of this rare opportunity to acquire as much equity as possible.

If you don't seize the opportunity to make a big splash this time, you won't know when the next time will be, and the cost will be extremely frightening by then!

Professor Herb Boyer was flattered by Xia Yu's flattery and felt very good about Xia Yu.

In the end, a huge expansion plan was made, and it was decided to inject a one-time capital of 50 million US dollars into the company!

After the capital injection, Xia Yu's shareholding ratio increased by 19.23%.

The total shareholding ratio increased to 77.83%.

And Professor Herb Boyle's shareholding ratio dropped from 41.4% to 22.17%!

At this point, Xia Yu can officially announce it!

Genentech, the hunt is successful!